Although the neurotransmitter dopamine plays a prominent role in the pathogenesis and treatment of schizophrenia, the dopamine hypothesis of schizophrenia fails to explain all aspects of this disorder. It is increasingly evident that the pathology of schizophrenia also involves other neurotransmitter systems. Data from many streams of research including pre-clinical and clinical pharmacology, treatment studies, post-mortem studies and neuroimaging suggest an important role for the muscarinic cholinergic system in the pathophysiology of schizophrenia. This review will focus on evidence that supports the hypothesis that the muscarinic system is involved in the pathogenesis of schizophrenia and that muscarinic receptors may represent promising novel targets for the treatment of this disorder.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
CNS Drugs Open Access 20 July 2023
Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
Psychopharmacology Open Access 10 April 2023
Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system
Translational Psychiatry Open Access 27 March 2023
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Goldberg TE, Gold JM, Greenberg R, Griffin S, Schulz SC, Pickar D et al. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry 1993; 150: 1355–1362.
Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR . Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000; 57: 907–913.
Siris SG . Depression in schizophrenia. In: Hirsch SR, Weinberger DR (eds). Schizophrenia. Blackwell Science Ltd.: Oxford, 1995, pp 128–146.
Green MF . What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321–330.
Carlsson A . The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179–186.
Creese I, Burt DR, Snyder SH . Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481–483.
Seeman P, Lee T, Chau-Wong M, Wong K . Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717–719.
Kapur S, Remington G . Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50: 873–883.
Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235–9240.
Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998; 155: 761–767.
Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94: 2569–2574.
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104–8109.
Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006; 49: 603–615.
Snyder SH . Dopamine receptor excess and mouse madness. Neuron 2006; 49: 484–485.
Olney JW, Farber NB . Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998–1007.
Konradi C, Heckers S . Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 2003; 97: 153–179.
Benes FM, Berretta S . GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001; 25: 1–27.
Meltzer HY . Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99: S18–S27.
Freedman R, Adams CE, Leonard S . The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J Chem Neuroanat 2000; 20: 299–306.
Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630–638.
Cooper JR, Bloom FE, Roth RH (eds). The Biochemical Basis of Neuropharmacology. Oxford University Press: New York, USA, 1996.
Sarter M, Parikh V . Choline transporters, cholinergic transmission and cognition. Nat Rev Neurosci 2005; 6: 48–56.
Mesulam MM, Mufson EJ, Levey AI, Wainer BH . Cortical innervation of cortex. J Comp Neurol 1983; 214: 170–197.
Perry E, Walker M, Grace J, Perry R . Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999; 22: 273–280.
Mesulam MM . The cholinergic innervation of the human cerebral cortex. Prog Brain Res 2004; 145: 67–78.
Deutsch JA . The cholinergic synapse and the site of memory. Science 1971; 174: 788–794.
Bartus RT, Dean III RL, Beer B, Lippa AS . The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–414.
Kozak R, Bruno JP, Sarter M . Augmented prefrontal acetylcholine release during challenged attentional performance. Cereb Cortex 2006; 16: 9–17.
Ellis JR, Ellis KA, Bartholomeusz CF, Harrison BJ, Wesnes KA, Erskine FF et al. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol 2006; 9: 175–178.
Minzenberg MJ, Poole JH, Benton C, Vinogradov S . Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004; 161: 116–124.
Dale HH . The action of certain esters and ethers of choline, and their relation to muscarine. J Pharmacol Exp Ther 1914; 6: 147–190.
Picciotto M, Caldarone BJ, King SL, Zachariou V . Nicotinic receptors in the brain: links between molecular biology and behavior. Neuropsychopharmacology 2000; 22: 451–465.
Popot JL, Sugiyame H, Changeux JP . Studies on the electrogenic action of acetylcholine with torpedo marmorata electric organ II. The permeability response of the receptor-rich membrane fragments to cholinergic agonists in vitro. J Mol Biol 1976; 106: 469–483.
Conti-Tronconi BM, Hunkapiller MW, Lindstrom JM, Raftery A . Subunit structure of the acetylcholine receptor from electrophorus electricus. Proc Natl Acad Sci USA 1982; 79: 6489–6493.
Felder CC . Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 1995; 9: 619–625.
Lucas-Meunier E, Fossier P, Baux G, Amar M . Cholinergic modulation of the cortical neuronal network. Pflugers Arch 2003; 446: 17–29.
Blaha CD, Allen LF, Das S, Inglis WL, Latimer MP, Vincent SR et al. Modulation of dopamine efflux in the nucleus accumbens after cholinergic stimulation of the ventral tegmental area in intact, pedunculopontine tegmental nucleus-lesioned and laterodorsal tegmental nucleus-lesioned rats. J Neurosci 1996; 16: 714–722.
Lokwan S, Overton P, Berry M, Berry MS, Clark D . Stimulation of the pedunculopontine tegmental nucleus in the rat produces burst firing in A9 dopaminergic neurons. Neuroscience 1999; 92: 245–254.
Wu M, Shanabrough M, Leranth C, Alreja M . Cholinergic excitation of septohippocampal GABA but not cholinergic neurons: implications for learning and memory. J Neurosci 2000; 20: 3900–3908.
Atzori M, Kanold PO, Pineda JC, Flores-Hernandez J, Paz RD . Dopamine prevents muscarinic-induced decrease of glutamate release in the auditory cortex. Neuroscience 2005; 134: 1153–1165.
Zhang W, Yamada M, Gomeza J, Basile AS, Wess J . Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1–M5 muscarinic receptor knock-out mice. J Neurosci 2002; 22: 6347–6352.
Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986; 323: 411–416.
Van Zwieten PA . Adrenergic and muscarinergic receptors: classification, pathophysiological relevance and drug target. J Hypertens 1991; 9: 518–527.
Spiegel AM, Shenker A, Weinstein LS . Receptor–effector coupling by g-proteins – implications for normal and abnormal signal transduction. Endocr Rev 1992; 13: 536–565.
Wess J . Molecular basis of muscarinic acetylcholine receptor function. Trends Pharmacol Sci 1993; 14: 308–313.
Raiteri M, Leardi R, Marchi M . Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J Pharmacol Exp Ther 1984; 228: 209–214.
Wamsley JK, Zarbin MA, Kuhar MJ . Distribution of muscarinic cholinergic high and low affinity agonist binding sites: a light microscopic autoradiographic study. Brain Res Bull 1984; 12: 233–243.
Vizi ES, Kobayashi O, Torocsik A, Kinjo M, Nagashima H, Manabe N et al. Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release. Neuroscience 1989; 31: 259–267.
Raiteri M, Marchi M, Paudice P, Pittaluga A . Muscarinic receptors mediating inhibition of γ-aminobutyric acid release in rat corpus striatum and their pharmacological characterization. J Pharmacol Exp Ther 1990; 254: 496–501.
Watling KJ, Kebabian JW, Neumeyer JL (eds). The RBI Handbook of Receptor Classification and Signal Transduction. Research Biochemicals International: Natick, MA, 1995.
Bonner TI, Buckley NJ, Young AC, Brann MR . Identification of a family of muscarinic acetylcholine receptor genes. Science 1987; 237: 527–532.
Bonner TI, Young AC, Brann MR, Buckley NJ . Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988; 1: 403–410.
Buckley NJ, Bonner TI, Buckley CM, Brann MR . Antagonist binding properties of five cloned muscarinic receptors expresses in CHO-K1 cells. Mol Pharmacol 1989; 35: 469–476.
Hulme EC, Birdsall NJM, Buckley NJ . Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 1990; 30: 633–673.
Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR . Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 1991; 11: 3218–3226.
Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI . Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 1995; 64: 1888–1891.
Flynn DD, Mash DC . Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse 1993; 14: 283–296.
Li M, Yasuda RP, Wall SJ, Wellstein A, Wolfe BB . Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors. Mol Pharmacol 1991; 40: 28–35.
Vilaro MT, Wiederhold K-H, Palacios JM, Mengod G . Mucarinic cholinergic receptors in the rat caudate-putamen and olfactory tubercle belong predominantly to the m4 class: in situ hybridization and receptor autoradiography evidence. Neuroscience 1991; 40: 159–167.
Wall SJ, Yasuda RP, Hory F, Flagg S, Martin BM, Ginns EI et al. Production of antisera selective for m1 muscarinic receptors using fusion proteins: distribution of m1 receptors in rat brain. Mol Pharmacol 1991; 39: 643–649.
Yasuda RP, Ciesla W, Flores LR, Wall SJ, Li M, Satkus SA et al. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 1993; 43: 149–157.
Buckley NJ, Bonner TI, Brann MR . Localization of a family of muscarinic receptor mRNAs in rat brain. J Neurosci 1988; 8: 4646–4652.
Liao CF, Themmen APN, Joho R, Barberis C, Birnbaumer M, Birnbaumer L . Molecular cloning and expression of a fifth muscarinic acetylcholine receptor. J Biol Chem 1989; 264: 7328–7337.
Vilaro MT, Palacios JM, Mengod G . Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci Lett 1990; 114: 154–159.
Miller AD, Blaha CD . Midbrain muscarinic receptor mechanisms underlying regulation of mesoaccumbens and nigrostriatal dopaminergic transmission in the rat. Eur J Neurosci 2005; 21: 1837–1846.
Mrzljak L, Levey AI, Goldman-Rakic PS . Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci USA 1993; 90: 5194–5198.
Baghdoyan HA, Lydic R, Fleegal MA . M2 muscarinic autoreceptors modulate acetylcholine release in the medial pontine reticular formation. J Pharmacol Exp Ther 1998; 286: 1446–1452.
Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J . Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 2002; 22: 1709–1717.
Stoll C, Schwarzwalder U, Johann S, Lambrecht G, Hertting G, Feuerstein TJ et al. Characterization of muscarinic autoreceptors in the rabbit hippocampus and caudate nucleus. Neurochem Res 2003; 28: 413–417.
Hamilton SE, Loose MD, Qi M, Levey AI, Hille B, McKnight GS et al. Disruption of the M1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc Natl Acad Sci USA 1997; 94: 13311–13316.
Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodkin J et al. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 1692–1697.
Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J et al. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 10483–10488.
Shapiro MS, Loose MD, Hamilton SE, Nathanson NM, Gomeza J, Wess J et al. Assignment of muscarinic receptor subtypes mediating G-protein modulation of Ca(2+) channels by using knockout mice. Proc Natl Acad Sci USA 1999; 96: 10899–10904.
Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003; 6: 51–58.
Bymaster FP, Carter PA, Yamada M, Gomeza J, Wess J, Hamilton SE et al. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci 2003; 17: 1403–1410.
Bymaster FP, McKinzie DL, Felder CC, Wess J . Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 2003; 28: 437–442.
Holt DJ, Herman MM, Hyde TM, Kleinman JE, Sinton CM, German DC et al. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 1999; 94: 21–31.
Holt DJ, Bachus SE, Hyde TM, Wittie M, Herman MM, Vangel M et al. Reduced density of cholinergic interneurons in the ventral striatum in schizophrenia: an in situ hybridization study. Biol Psychiatry 2005; 58: 408–416.
Karson CN, Casanova MF, Kleinman JE, Griffin WS . Choline acetyltransferase in schizophrenia. Am J Psychiatry 1993; 150: 454–459.
Garcia-Rill E, Biedermann JA, Chambers T, Skinner RD, Mrak RE, Husain M et al. Mesopontine neurons in schizophrenia. Neuroscience 1995; 66: 321–335.
German DC, Manaye KF, Wu D, Hersh LB, Zweig RM . Mesopontine cholinergic and non-cholinergic neurons in schizophrenia. Neuroscience 1999; 94: 33–38.
Bennett Jr JP, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH . Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979; 36: 927–934.
Watanabe S, Nishikawa T, Takashima M, Toru M . Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 1983; 33: 2187–2196.
Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 1988; 78: 121–137.
Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL . The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1996; 1: 54–58.
Crook JM, Dean B, Pavey G, Copolov D . The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 1999; 64: 1761–1771.
Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B . Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000; 48: 381–388.
Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B . Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158: 918–925.
Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E . Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002; 7: 1083–1091.
Scarr E, Keriakous D, Crossland N, Dean B . No change in cortical muscarinic M2, M3 receptors or [(35)S]GTPgammaS binding in schizophrenia. Life Sci 2006; 78: 1231–1237.
Scarr E, Sundram S, Keriakous D, Dean B . Changes in muscarinic M4, but not M1, receptor expression in the hippocampus from subjects with schizophrenia. Biol Psychiatry (in press).
Zavitsanou K, Katsifis A, Yu Y, Huang XF . M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 2005; 65: 397–403.
Katerina Z, Andrew K, Filomena M, Xu-Feng H . Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004; 29: 619–625.
Deng C, Huang XF . Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 2005; 81: 883–890.
Mancama D, Arranz MJ, Landau S, Kerwin R . Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 119: 2–6.
Dean B, Crook JM, Pavey G, Opeskin K, Copolov DL . Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia. Mol Psychiatry 2000; 5: 203–207.
Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003; 160: 118–127.
Raedler TJ, Knable MB, Jones DW, Lafargue T, Urbina RA, Egan MF et al. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 2000; 23: 56–68.
Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA . Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berlin) 2001; 156: 53–57.
Raedler TJ, Knable MB, Jones DW, Urbina RA, Egan MF, Weinberger DR . Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 2003; 28: 1531–1537.
Raedler TJ . Comparison of the in vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine. Int J Neuropsychopharmacol 2006; doi:10.1017/S1461145706006584.
Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87–96.
Nobuhara K, Farde L, Halldin C, Karlsson P, Swahn CG, Olsson H et al. SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP. Eur J Nucl Med 2001; 28: 13–24.
Jagoda EM, Kiesewetter DO, Shimoji K, Ravasi L, Yamada M, Gomeza J et al. Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology 2003; 44: 653–661.
Perry EK, Perry RH . Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995; 28: 240–258.
Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DGC, Bourne RC et al. Adverse effects of anticholinergic agents on positive symptoms. Psychol Med 1983; 13: 513–527.
Singh MM, Kay SR, Opler LA . Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia. Psychol Med 1987; 17: 39–48.
Chouinard G, Annable L, Mercier P, Turnier L . Long-term effects of L-dopa and procyclidin on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull 1987; 23: 221–226.
Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson J . Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophr Res 1991; 4: 23–30.
Tandon R, DeQuardo JR, Goodson J, Mann NA, Greden JF . Effect of anticholinergics on positive and negative symptoms in schizophrenia. Psychopharmacol Bull 1992; 28: 297–302.
Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR et al. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 1993; 90: 11816–11820.
Zemishlany Z, Aizenberg D, Weiner Z, Weizman A . Trihexyphenidyl (Artane) abuse in schizophrenic patients. Int Clin Psychopharmacol 1996; 11: 199–202.
Zarcone Jr VP, Benson KL, Berger PA . Abnormal rapid eye movement latencies in schizophrenia. Arch Gen Psychiatry 1987; 44: 45–48.
Tandon R, Shipley J, Taylor SF, Greden JF, Eiser A, DeQuardo JR et al. Electroencephalographic abnormalities in schizophrenia. Arch Gen Psychiatry 1992; 49: 185–194.
Riemann D, Hohagen F, Krieger S, Gann H, Muller WE, Olbrich R et al. Cholinergic REM induction test: muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia. J Psychiatr Res 1994; 28: 195–210.
Tandon R . Cholinergic aspects of schizophrenia. Br J Psychiatry 1999; 174(Suppl 37): 7–11.
O'Keane V, Abel K, Murray RM . Growth hormone responses to pyridostigmine in schizophrenia: evidence for cholinergic dysfunction. Biol Psychiatry 1994; 36: 582–588.
Tandon R, Greden JF . Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989; 46: 745–753.
Yeomans JS . Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995; 12: 3–16.
Harvey PD, Keefe RS . Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176–184.
Jibson MD, Tandon R . New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215–228.
Brebion G, Bressan RA, Amador X, Malaspina D, Gorman JM . Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med 2004; 34: 369–374.
Cummings JL, Cole G . Alzheimer disease. JAMA 2002; 287: 2335–2338.
Friedman JI . Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berlin) 2004; 174: 45–53.
Stryjer R, Strous RD, Bar F, Werber E, Shaked G, Buhiri Y et al. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol 2003; 26: 12–17.
Stryjer R, Strous R, Bar F, Shaked G, Shiloh R, Rozencwaig S et al. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Hum Psychopharmacol 2004; 19: 343–346.
Buchanan RW, Summerfelt A, Tek C, Gold J . An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 2003; 59: 29–33.
Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA . Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol 2005; 28: 179–184.
Nahas Z, George MS, Horner MD, Markowitz JS, Li X, Lorberbaum JP et al. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase 2003; 9: 274–282.
Caroff S, Campbell E, Havey J, Sullivan KA, Mann SC, Gallop R . Treatment of tardive dyskinesia with donepezil: a pilot study. J Psychiatry 2001; 62: 772–775.
Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002; 51: 349–357.
Tugal O, Yazici KM, Yagcioglu AE, Gogus A . A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 2004; 7: 117–123.
Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berlin) 2005; 181: 358–363.
Lenzi A, Maltinti E, Poggi E, Fabrizio L, Coli E . Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol 2003; 26: 317–321.
Aasen I, Kumari V, Sharma T . Effects of rivastigmine on sustained attention in schizophrenia: an fMRI study. J Clin Psychopharmacol 2005; 25: 311–317.
Sharma T, Reed C, Aasen I, Kumari V . Cognitive effects of adjuctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation. Schizophr Res 2006; 85: 73–83.
Bora E, Veznedaroğlu B, Kayahan B . The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 2005; 28: 139–141.
Sullivan RJ, Allen JS, Otto C, Tiobech J, Nero K . Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia. Br J Psychiatry 2000; 177: 174–178.
Mirza NR, Peters D, Sparks RG . Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 2003; 9: 159–186.
Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH et al. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther 1999; 290: 901–907.
Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD et al. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 2000; 42: 249–259.
Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 2001; 299: 782–792.
Andersen MB, Fink-Jensen A, Peacock L, Gerlach J, Bymaster F, Lundbaek JA et al. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 2003; 28: 1168–1175.
Grant MK, El-Fakahany EE . Persistent binding and functional antagonism by xanomeline at the muscarinic m5 receptor. J Pharmacol Exp Ther 2005; 315: 313–319.
Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54: 465–473.
Shekhar A, Potter WZ, Lienemann J, Sundblad K, Lightfoot J, Herrera J et al. Efficacy of xanomeline, a selective muscarinic agonist, in treating schizophrenia: a double-blind, placebo controlled study. Abstract 40th Annual Meeting ACNP, Hawaii, December 9–13, 2001.
Kane JM, Honigfeld G, Singer J, Meltzer HY . Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.
Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY . Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702–712.
Goldberg TE, Weinberger DR . The effects of clozapine on neurocognition: an overview. J Clin Psychiatry 1994; 55(Suppl B): 88–90.
Fritze J, Elliger T . Pirenzepine for clozapine-induced hypersalivation. Lancet 1995; 346: 1034.
Schneider B, Weigmann H, Hiemke C, Weber B, Fritze J . Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 2004; 37: 43–45.
Tandon R . Effects of atypical antipsychotics on polysomnographic measures in schizophrenia. Bibliotheca Psychiatrica 1997; 167: 219–222.
Tandon R, Kane JM . Neuropharmacological basis of clozapine's mechanism of action. Arch Gen Psychiatry 1993; 50: 157–159.
Zorn SH, Jones SB, Ward KM, Liston DR . Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 1994; 269: R1–R2.
Zeng XP, Le F, Richelson E . Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 1997; 321: 349–354.
Michal P, Lysikova M, El-Fakahany EE, Tucek S . Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors. Eur J Pharmacol 1999; 376: 119–125.
Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 1999; 37: 107–122.
Olianas MC, Maullu C, Onali P . Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol 1997; 122: 401–408.
Meltzer HY, Chai BL, Thompson PA, Yamamoto BK . Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol, or thioridazine. J Pharm Exp Ther 1994; 268: 1452–1461.
Olianas MC, Maullu C, Onali P . Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology 1999; 20: 263–270.
Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 2004; 177: 207–216.
Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL . The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berlin) 2005; 178: 451–460.
Burstein ES, Ma JN, Wong S, Gao Y, Pham E, Knapp AE et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 2005; 15: 1272–1278.
Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY . N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M(1) muscarinic receptors. Neuropsychopharmacology 2005; 30: 1986–1995.
Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 2003; 100: 13674–13679.
Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY . Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002; 26: 325–339.
Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J . Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res 2004; 1023: 54–63.
Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV . Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berlin) 2004; 174: 3–16.
Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP . The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry 2001; 49: 716–725.
Di Chiara G, Morelli M, Consolo S . Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 1994; 17: 228–233.
Kaneko S, Hikida T, Watanabe D, Ichinose H, Nagatsu T, Kreitman RJ et al. Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science 2000; 289: 633–637.
Zhou F-M, Wilson C, Dani JA . Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 2003; 9: 23–36.
Fahn S, Burke R, Stern Y . Antimuscarinic drugs in the treatment of movement disorders. Prog Brain Res 1990; 84: 389–397.
Sugita S, Uchimura N, Jiang ZG, North RA . Distinct muscarinic receptors inhibit release of γ-aminobutyric acid and excitatory amino acids in mammalian brain. Proc Natl Acad Sci USA 1991; 88: 2608–2611.
Bolam JP, Francis CM, Henderson Z . Cholinergic input to dopaminergic neurons in the substantia nigra: a double immunocytochemical study. Neuroscience 1991; 41: 483–494.
De Klippel N, Sarre S, Ebinger G, Michotte Y . Effect of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism: an in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats. Brain Res 1993; 630: 57–64.
Gronier B, Rasmussen K . Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat. Br J Pharmacol 1998; 124: 455–464.
Weiner DM, Levey AI, Brann MR . Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 1990; 87: 7050–7054.
Gronier B, Perry KW, Rasmussen K . Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area. Psychopharmacology (Berlin) 2000; 147: 347–355.
Lehmann J, Langer SZ . Muscarinic receptors on dopamine terminals in the cat caudate nucleus: neuromodulation of [3H]dopamine release in vitro by endogenous acetylcholine. Brain Res 1982; 248: 61–69.
Gronier B, Rasmussen K . Pertussis toxin treatment differentially affects cholinergic and dopaminergic receptor stimulation of midbrain dopaminergic neurons. Neuropharmacology 1999; 38: 1903–1912.
Fiorillo CD, Williams JT . Cholinergic inhibition of ventral midbrain dopamine neurons. J Neurosci 2000; 20: 7855–7860.
Ichikawa J, Chung Y-C, Li Z, Dai J, Meltzer HY . Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 2002; 958: 176–184.
Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S . Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 2001; 98: 15312–15317.
Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 2004; 18: 1410–1412.
Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS et al. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. Eur J Pharmacol 1998; 356: 109–119.
Rasmussen T, Fink-Jensen A, Sauerberg P, Swedberg MD, Thomsen C, Sheardown MJ et al. The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance. Schizophr Res 2001; 49: 193–201.
Jones CK, Shannon HE . Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J Pharmacol Exp Ther 2000; 294: 1017–1023.
Swerdlow NR, Braff DL, Taaid N, Geyer MA . Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994; 51: 139–154.
Jones CK, Eberle EL, Shaw DB, McKinzie DL, Shannon HE . Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther 2005; 312: 1055–1063.
Sarter M, Nelson CL, Bruno JP . Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull 2005; 31: 117–138.
Laplante F, Nakagawasai O, Srivastava LK, Quirion R . Alterations in behavioral responses to a cholinergic agonist in post-pubertal rats with neonatal ventral hippocampal lesions: relationship to changes in muscarinic receptor levels. Neuropsychopharmacology 2005; 30: 1076–1087.
Borda T, Perez Rivera R, Joensen L, Gomez RM, Sterin-Borda L . Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J Immunol 2002; 168: 3667–3674.
Tanaka S, Matsunaga H, Kimara M, Tatsumi K, Hidaka Y, Takano T et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol 2003; 141: 155–164.
Borda T, Gomez R, Berria MI, Sterin-Borda L . Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia 2004; 45: 144–154.
Ganzinelli S, Borda T, Sterin-Borda L . Regulation of m1 muscarinic receptors and nNOS mRNA levels by autoantibodies from schizophrenic patients. Neuropharmacology 2006; 50: 362–371.
Scolnick EM . Mechanisms of action of medicines for schizophrenia and bipolar illness: status and limitations. Biol Psychiatry 2006; 59: 1039–1145.
Leonard S, Freedman R . Genetics of chromosome 15q13–q14 in schizophrenia. Biol Psychiatry 2006; 60: 115–122.
De Luca V, Wang H, Squassina A, Wong GW, Yeomans J, Kennedy JL . Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology 2004; 50: 124–127.
Liao DL, Hong CJ, Chen HM, Chen YE, Lee SM, Chang CY et al. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003; 48: 72–76.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223.
About this article
Cite this article
Raedler, T., Bymaster, F., Tandon, R. et al. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 12, 232–246 (2007). https://doi.org/10.1038/sj.mp.4001924
- muscarinic agonists
- muscarinic antagonists
This article is cited by
Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system
Translational Psychiatry (2023)
Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
CNS Drugs (2023)
The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain
InFo Neurologie + Psychiatrie (2021)